Effect of prazosin on diabetic nephropathy patients with positive α1‑adrenergic receptor autoantibodies and refractory hypertension

Zhao,Lin-Shuang; Xu,Chun-Yan

doi:10.3892/etm.2014.2036

Effect of prazosin on diabetic nephropathy patients with positive α1‑adrenergic receptor autoantibodies and refractory hypertension

Authors:
- Lin-Shuang Zhao
- Chun-Yan Xu
View Affiliations

Affiliations: Department of Endocrinology, Guangzhou Command Wuhan General Hospital, Wuhan, Hubei 430070, P.R.China, Graduate College, Southern Medical University, Guangzhou, Guangdong 510515, P.R.China
Published online on: October 27, 2014 https://doi.org/10.3892/etm.2014.2036
Pages: 177-182

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To investigate the effect of prazosin on patients with diabetic nephropathy (DN), α1‑adrenergic receptor (α1‑R) autoantibodies and refractory hypertension, a total of 126 patients with DN and hypertension were recruited. The patients were divided into a refractory hypertension group, (n=76) and a non‑refractory hypertension group (n=50). The epitope of the second extracellular loop of the α1‑R (192‑218) was synthesized and an enzyme‑linked immunosorbent assay (ELISA) was performed to detect serum autoantibodies. In the group with DN‑associated refractory hypertension, the positive rate of autoantibodies against the α1‑R was 80.3% (n=61). The 61 patients who were positive for α1‑R autoantibodies were randomly divided into a treatment group (n=31) and a control group (n=30). The patients were given drugs at the same dosage and administration, with the exception of prazosin, which was provided only to the patients in the treatment group [1 mg, three times a day (tid)] for a duration of six weeks. Subsequently, prazosin was added (1 mg, tid) to the therapeutic schedule of the patients in the control group and the α1‑R autoantibody‑negative group for another six weeks. The analysis was carried out on an intention‑to‑treat basis. The prazosin treatment resulted in significant improvements in hypertension in the treatment group (P<0.05), while there was no marked improvement in the control group. The total effective rate of hypertension improvement was 90.3% in the treatment group, which was higher compared with that of the control group (33.3%). In conclusion, α1‑R autoantibodies may play an important role in the pathogenesis of DN with refractory hypertension. Prazosin was demonstrated to be effective and safe in the treatment of DN with refractory hypertension.

View Figures

View References

1	Tabák AG, Herder C, Rathmann W, Brunner EJ and Kivimäki M: Prediabetes: A high-risk state for developing diabetes. Lancet. 379:2279–2290. 2012. View Article : Google Scholar
2	Weir MR: Salt, hypertension, and proteinuria in diabetic nephropathy. Lancet Diabetes Endocrinol. 2:351–352. 2014. View Article : Google Scholar : PubMed/NCBI
3	Dragun D, Philippe A, Catar R and Hegner B: Autoimmune mediated G-protein receptor activation in cardiovascular and renal pathologies. Thromb Haemost. 101:643–648. 2009.PubMed/NCBI
4	Smith SO: Structure and Activation of the Visual Pigment Rhodopsin. Ann Rev Biophys. 39:309–328. 2010. View Article : Google Scholar
5	Hilme E, Hansson L, Sanberg L, Söderström T and Herlitz H: Abnormal immune function in malignant hypertension. J hyper tens. 11:989–994. 1993. View Article : Google Scholar
6	Dragun D, Philippe A, Catar R and Hegner B: Autoimmune mediated G-protein receptor activation in cardiovascular and renal pathologies. Thromb Haemost. 101:643–648. 2009.PubMed/NCBI
7	Sun YX, Zhu F, Wang M, Li ZZ and Liao YH: Increased autoantibody production against AT(1)-receptors and alpha(1)-adrenergic receptors in hypertensive patients. Zhonghua Xin Xue Guan Bing Za Zhi. 36:16–19. 2008.(In Chinese). PubMed/NCBI
8	Zhao LS, Xiang GD, Yue L, Liao YH, Zhou ZH and Sun HL: Clinical effects of valsartan treatment on refractory hypertension with the positive autoantibody of AT1 receptor in diabetes mellitus patients. Chin J Diabetes. 16:607–610. 2008.(In Chinese).
9	Zhao LS, Bai WW, Xiang GD, Yue L and Sun HL: Clinical evaluation of valsartan and metoprolol tartrate in treatment of diabetic nephropathy with positive beta1-adrenergic and anti-angiotensin II type 1 receptor antibody. Chin Med J (Engl). 125:3543–3547. 2012.
10	Qiu Y, Zhu F, Liao YH, Li ZZ and Wang M: Association between positive autoantibodies against AT1-receptor and cardiac remodeling in patients with hypertension. Zhonghua Xin Xue Guan Bing Za Zhi. 35:1141–1144. 2007.
11	Zhu F, Sun YX, Liao YH, Wei YM, Chen M, Wang M and Zhou ZH: Agonistic AT(1) receptor autoantibody increases in serum of patients with refractory hypertension and improves Ca(2+) mobilization in cultured rat vascular smooth muscle cells. Cell Mol Immunol. 5:209–217. 2008. View Article : Google Scholar : PubMed/NCBI
12	Li LD, Tian M, Liao YH, Zhou ZH, Wei F, Zhu F, Wang M, Wang B and Wei YM: Effect of active immunization against angiotensin II type 1 (AT1) receptor on hypertension & arterial remodelling in spontaneously hypertensive rats (SHR). Indian J Med Res. 139:619–624. 2014.PubMed/NCBI
13	Wangensteen R, O’Valle F, Del MR, Vargas F and Osuna A: Chronic alpha1-adrenergic blockade improves hypertension and renal injury in L-NAME and low-renin L-NAME-DOCA hypertensive rats. Med Sci Monit. 8:378–384. 2002.
14	Chalmers J: The 1999 WHO-ISH Guidelines for the Management of Hypertension. Med J Australia. 171:4581999.
15	Mogensen MM, Tucker JB and Stebbings H: Microtubule polarities indicate that nucleation and capture of microtubules occurs at cell surfaces in Drosophila. J Cell Biol. 108:1445–1452. 1989. View Article : Google Scholar : PubMed/NCBI
16	Liao YH, Wei YM, Wang M, Wang ZH, Yuan HT and Cheng LX: Autoantibodies against AT1 receptor and α1 adrenergic receptor in patients with hypertension. Hypertens Res. 25:641–646. 2002. View Article : Google Scholar : PubMed/NCBI
17	Writing group of 2010 Chinese guidelines for the management of hypertension. 2010 Chinese guidelines for the management of hypertension. Chin J Hypertens. 19:701–743. 2011.
18	Wallukat G and Schimke I: Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases. Semin Immunopathol. 36:351–363. 2014. View Article : Google Scholar : PubMed/NCBI
19	Shi L and Javitch JA: The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu Rev Pharmacol Toxicol. 42:437–467. 2002. View Article : Google Scholar : PubMed/NCBI
20	Piali L and Richardson DR: G-protein coupled receptors: drug targets of key importance. Curr Top Med Chem. 11:6082011. View Article : Google Scholar : PubMed/NCBI
21	Thomas GN, Chan P and Tomlinson B: The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension. Drug Aging. 23:131–155. 2006. View Article : Google Scholar
22	Randle LE, Sathish JG, Kitteringham NR, Macdonald I, Williams DP and Park BK: alpha(1)-Adrenoceptor antagonists prevent paracetamol-induced hepatotoxicity in mice. Br J Pharmacol. 153:820–830. 2008. View Article : Google Scholar
23	Zhou ZH, Qi Q, Liao YH, Wang B, Li LD, Wei F, Wang M and Wei YM: Preparation of the antibodies against alpha 1-adrenergic receptor with exciting actions. Chinese J Clin Rehabil. 10:51–54. 2006.(In Chinese).
24	Iwata M, Yoshikawa T, Baba A, Anzai T, Nakamura I, Wainai Y, Takahashi T and Ogawa S: Autoimmunity against the second extracellular loop of beta(1)-adrenergic receptors induces beta-adrenergic receptor desensitization and myocardial hypertrophy in vivo. Circ Res. 88:578–586. 2001. View Article : Google Scholar : PubMed/NCBI
25	Fu ML, Herlitz H, Schulze W, et al: Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens. 18:945–953. 2000. View Article : Google Scholar : PubMed/NCBI
26	Ogihara T, Asano T, Ando K, et al: Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension. 40:872–879. 2002. View Article : Google Scholar : PubMed/NCBI
27	Touyz RM and Schiffrin EL: Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 52:639–672. 2000.PubMed/NCBI
28	Dzielak DJ: Immune mechanisms in experimental and essential hypertension. Am J Physiol. 260:R459–R467. 1991.PubMed/NCBI
29	Shen KP, Lin HL, Hsieh SL, Kwan AL, Chen IJ and Wu BN: Eugenosedin-A prevents hyperglycaemia, hyperlipidaemia and lipid peroxidation in C57BL/6J mice fed a high-fat diet. J Pharm Pharmacol. 61:517–525. 2009. View Article : Google Scholar : PubMed/NCBI
30	Liao CH, Guh JH, Chueh SC, et al: Anti-angiogenic effects and mechanism of prazosin. Prostate. 71:976–984. 2011. View Article : Google Scholar : PubMed/NCBI